FDA Authorizes First Extensions of Doxycycline Held in Stakeholder Stockpiles

Under the Food and Drug Administration’s (FDA) April 2017 draft guidance Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles, the first two-year extensions were authorized by FDA on Aug. 22, based on a request received from a stakeholder that tested five lots of its properly stockpiled Doxycycline for anthrax preparedness. The same extensions of these five lots will apply to any government stakeholder (as defined in the draft guidance and extension memo) that is properly holding the same lot numbers.

For more information, please visit FDA’s Medical Countermeasure Dating Extension web page. Details of the extension authorization of the five specific lots of Doxycycline are included in FDA’s extension memo issued on Aug. 22.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.